XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
X4 Pharmaceuticals, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.75+0.16 (+6.18%)
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
X4 Pharmaceuticals, Inc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q1 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and other revenue | $6.43M | $239.00K | $297.00K | $199.00K | $229.00K | $27.87M | $0 | $0 | $0 | $0 | – | – | 268.0% | +2709.2% |
| Product revenue, net | $2.37M | $2.47M | $2.27M | $1.57M | $1.74M | $942.00K | $1.43M | $560.00K | $563.00K | $0 | – | – | 98.9% | +36.1% |
By region
From the segment and revenue-disaggregation notes of X4 Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.